Novartis AG
Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents

Abstract:

The present invention provides a compound of Formula (I): ##STR00001## or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).